Full Press Release Details
Biopharma Completes Scientific Advice Meeting with MHRA
Receives Guidance on the Investigational Medicinal Product Manufacturing Program for PRP.
AUSTRALIA, April 10, 2018-- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or the
"Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments
for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the
completion of a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, regarding
the investigational medicinal product (IMP) manufacturing program for PRP, the Company's lead product candidate. A
number of topics were raised and clarified regarding the preparation of a clinical trial application (CTA) for a
First-In-Human study in the UK. Key topics included the definition of starting material under Good Manufacturing Practice
(GMP) principles, as well as certain tests to be conducted as part of the ongoing quality assurance and control requirements
for manufacture of a biological product for human use.
meeting with the MHRA was a very important step for the Company, as it helped us to clarify the requirements for our upcoming
IMP manufacture of PRP," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "Our Management
team continues to work closely with our development partners to conduct the necessary activities that we believe, with the right
justification, will support the approval of our first CTA in the UK."
is a solution for intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Currently
progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent
of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization,
8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the
global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient
populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in
2020, according to GBI Research.
view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on
the following link: http: //www.propanc.com/news-media/video
be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts
and submit the online request form.
Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from
pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of
effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ
pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining
therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product candidate to treat (i)
early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer
based on genetic screening. For more information, visit: www.propanc.com.
statements other than statements of historical fact contained herein are "forward-looking statements" for purposes of
federal and state securities laws. Forward-looking statements may include the words "may," "will," "estimate,"
"intend," "continue," "believe," "expect," "plan" or "anticipate"
and other similar words. Although we believe that the expectations reflected in our forward-looking statements are reasonable,
actual results could differ materially from those projected or assumed. Our future financial condition and results of operations,
as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties including those regarding
our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives for future operations,
our ability to execute on proposed new products, services or development thereof, our ability to establish and maintain the proprietary
nature of our technology through the patent process, our ability to license from others patents and patent applications, if necessary,
to develop certain products, our ability to implement our long range business plan for various applications of our technology,
our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of
commercialization, the results of our clinical research and development, competition in the industry in which we operate, overall
market conditions, and any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that
could cause actual results to differ materially from those projected may be described from time to time in reports we file with
the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no
obligation, to update any forward-looking statement contained herein, except as required by law.